Applied dna extends application of linea(tm) ivt platform to sarna (self-amplifying mrna)

- extension increases total addressable market to include both conventional non-amplifying mrna and sarna - - extension enabled by the company's ongoing platform development and optimization - stony brook, ny / accesswire / november 16, 2023 / applied dna sciences, inc. (nasdaq:apdn) ("applied dna" or the "company"), a leader in pcr-based dna technologies, announced the expansion of its linea™ ivt platform (the "platform") to include the manufacture of self-amplifying mrna ("sarna"). launched in july 2023, the platform was previously optimized for smaller conventional non-amplifying mrna constructs that currently comprise the bulk of demand for mrna.
APDN Ratings Summary
APDN Quant Ranking